Recently, the development of low molecular weight heparin fractions and fragments. (LMHF) as potential anti-thrombotic agents has gained increased attention. However, the lack of antagonists to neutralize the anti-coagulant effects of these drugs may seriously exclude them from possible uses in extracorporeal therapy. This is mainly because of the concern that the high dosage of the drugs employed in extracorporeal therapy could lead to serious bleeding risks. Our earlier work has demonstrated that immobilized heparinase can remove polydis-perse heparin both and . To examine whether such a system may be used as a novel approach to neutralize the anticoagulant effects of LMHF, different LMMF were tested using heparinase. data showed that b...
Background: Heparins in clinical use differ considerably as to mode of preparation, molecular weight...
Heparin consists of different classes of molecules. We distinguish below-critical-chain length hepar...
Heparins inhibit the thrombin forming capacity of plasma, i. e., the endogenous thrombin potential (...
Anticoagulant therapy with heparin has been the cornerstone of treatment and prevention of thrombosi...
Low-molecular-weight heparins (LMWHs) are carbohydrate-based anticoagulants clinically used to treat...
Low-molecular-weight heparins (LMWHs) are carbohydrate-based anticoagulants clinically used to treat...
Introduction. For a long time, the main medication for treating and preventing of thrombotic complic...
Heparins represent one of the most frequently used pharmacotherapeutics. Discovered around 1926, rou...
Unfractionated heparin (UFH) is mostly obtained from porcine and bovine mucosa and has been widely u...
Protamine, the only registered antidote of unfractionated heparin (UFH), may produce a number of adv...
Heparin, a negatively charged sulphated glycosaminoglycan, is clinically the most important antithro...
Heparins exert anticoagulation by potentiating anti-factor (F)Xa and anti-thrombin activity of antit...
<p><sup>a</sup>The shorter the LMWH fragments, the more specific the agent is for factor Xa [<a href...
Les héparines regroupant les héparines standards (HNF), les héparines de bas poids moléculaire(HBPM)...
Three fractions of the low molecular weight heparin CY2l6 (fraxiparin, mean molecular weight [MMW] 5...
Background: Heparins in clinical use differ considerably as to mode of preparation, molecular weight...
Heparin consists of different classes of molecules. We distinguish below-critical-chain length hepar...
Heparins inhibit the thrombin forming capacity of plasma, i. e., the endogenous thrombin potential (...
Anticoagulant therapy with heparin has been the cornerstone of treatment and prevention of thrombosi...
Low-molecular-weight heparins (LMWHs) are carbohydrate-based anticoagulants clinically used to treat...
Low-molecular-weight heparins (LMWHs) are carbohydrate-based anticoagulants clinically used to treat...
Introduction. For a long time, the main medication for treating and preventing of thrombotic complic...
Heparins represent one of the most frequently used pharmacotherapeutics. Discovered around 1926, rou...
Unfractionated heparin (UFH) is mostly obtained from porcine and bovine mucosa and has been widely u...
Protamine, the only registered antidote of unfractionated heparin (UFH), may produce a number of adv...
Heparin, a negatively charged sulphated glycosaminoglycan, is clinically the most important antithro...
Heparins exert anticoagulation by potentiating anti-factor (F)Xa and anti-thrombin activity of antit...
<p><sup>a</sup>The shorter the LMWH fragments, the more specific the agent is for factor Xa [<a href...
Les héparines regroupant les héparines standards (HNF), les héparines de bas poids moléculaire(HBPM)...
Three fractions of the low molecular weight heparin CY2l6 (fraxiparin, mean molecular weight [MMW] 5...
Background: Heparins in clinical use differ considerably as to mode of preparation, molecular weight...
Heparin consists of different classes of molecules. We distinguish below-critical-chain length hepar...
Heparins inhibit the thrombin forming capacity of plasma, i. e., the endogenous thrombin potential (...